Moexipril 7.5mg tablets

Objective: The goal of this study is to see if moexipril can protect rats against renal ischemia/reperfusion injury. Methods: Overall twenty-eight males of rats were divided randomly into four groups (7 rat each group). Sham group: Except for ischemiainduction, these rats underwent IP anesthesia and surgery. Induced group: This group rats were anesthetized and given a midlinelaparotomy to induce bilateral renal ischemia for 30 min and 2 hours of reperfusion. DMSO group: Rats received DMSO IP injection 30 minbefore ischemia and subjected to 30 min bilateral ischemia and reperfusion for 2 hours, DMSO is a vehicle of moexipril and considered ascontrol. Moexipril group (pretreated group): moexipril was given in a dose 0.3 mg/kg I.P. injection 30 min before ischemia. Results: Renal IRI as indicated by a significant increase (P < 0.05) in urea, creatinine, NF-KB P65, IL-1β, and caspase-3 level, while GSH,SOD, and Bcl-2 levels significantly (P < 0.05) reduced in Renal tissues of rats in the induced group compared to sham group. Moexiprilpretreatment significantly (P < 0.05) ameliorate RIRI as suggested from significant lowering in urea, creatinine, and inflammatory markers(NF-KB P65 and IL-1β). The renal level of oxidative marker (SOD and GSH) and anti-apoptotic marker Bcl-2 were significant decreased(P < 0.05) and also significantly increase (P < 0.05) in caspase-3 level with moexipril group in comparison to induced group. Conclusion: By inhibiting oxidative stress, inflammation, and the apoptotic pathway, moexipril significantly protect from renal ischemiareperfusion in rats.

Abstract licence: CC BY-NC 4.0

Abstract The advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, has promoted physical and mental health worldwide. Due to the unavailability of effective antiviral drugs, there is an unmet demand for a robust therapeutic approach for the development of anti-SARS-CoV-2 drugs. Myriad investigations have recognized ACE2 as the primary receptor of SARS-CoV-2, and this amalgamation of ACE2 with the spike protein of the subsequent coronavirus is paramount for viral entry into host cells and inducing infection. Consequently, limiting or restricting the accessibility of the causal virus to ACE2 offers an alternative therapeutic approach for averting this illness. Thus, the objective of the study was to determine the highly efficacious inhibitors exhibiting an augmented affinity for ACE2 protein and asses their pharmacological efficacy using molecular docking analysis. Machine learning algorithms were employed to govern the novel compounds by taking the ACE2-inhibiting compounds, Quninaprill, Moexipril, etc, and pre-established repurposed viral compounds, Birinapant, Remdesivir, etc., as test datasets. Structural stability was further confirmed via MD simulation approach which comparatively assessed the novel machine-learning, and pre-established compounds, followed by toxicity and pharmacophore studies. The study therefore concludes that the novel machine-learning compound (PubChem ID: 23658468) can be a potent therapeutic agent for combatting SARS-CoV-2.

Abstract licence: CC BY